TY - JOUR
T1 - MR imaging features of retinoblastoma: Association with gene expression profiles
T2 - Association with Gene Expression Profiles
AU - Jansen, Robin W.
AU - de Jong, Marcus C.
AU - Kooi, Irsan E.
AU - Sirin, Selma
AU - Göricke, Sophia
AU - Brisse, Hervé J.
AU - Maeder, Philippe
AU - Galluzzi, Paolo
AU - van der Valk, Paul
AU - Cloos, Jacqueline
AU - Eekhout, Iris
AU - Castelijns, Jonas A.
AU - Moll, Annette C.
AU - Dorsman, Josephine C.
AU - de Graaf, Pim
PY - 2018/8
Y1 - 2018/8
N2 - Purpose: To identify associations between magnetic resonance (MR) imaging features and gene expression in retinoblastoma. Materials and Methods: A retinoblastoma MR imaging atlas was validated by using anonymized MR images from referral centers in Essen, Germany, and Paris, France. Images were from 39 patients with retinoblastoma (16 male and 18 female patients [the sex in five patients was unknown]; age range, 5–90 months; inclusion criterion: pretreatment MR imaging). This atlas was used to compare MR imaging features with genome-wide messenger RNA (mRNA) expression data from 60 consecutive patients obtained from 1995 to 2012 (35 male patients [58%]; age range, 2–69 months; inclusion criteria: pretreatment MR imaging, genome-wide mRNA expression data available). Imaging pathway associations were analyzed by means of gene enrichment. In addition, imaging features were compared with a predefined gene expression signature of photoreceptorness. Statistical analysis was performed with generalized linear modeling of radiology traits on normalized log2-transformed expression values. P values were corrected for multiple hypothesis testing. Results: Radiogenomic analysis revealed 1336 differentially expressed genes for qualitative imaging features (threshold P = .05 after multiple hypothesis correction). Loss of photoreceptorness gene expression correlated with advanced stage imaging features, including multiple lesions (P = .03) and greater eye size (P , .001). The number of lesions on MR images was associated with expression of MYCN (P = .04). A newly defined radiophenotype of diffuse-growing, plaque-shaped, multifocal tumors displayed overexpression of SERTAD3 (P = .003, P = .049, and P = .06, respectively), a protein that stimulates cell growth by activating the E2F network. Conclusion: Radiogenomic biomarkers can potentially help predict molecular features, such as photoreceptorness loss, that indicate tumor progression. Results imply a possible role for radiogenomics in future staging and treatment decision making in retinoblastoma.
AB - Purpose: To identify associations between magnetic resonance (MR) imaging features and gene expression in retinoblastoma. Materials and Methods: A retinoblastoma MR imaging atlas was validated by using anonymized MR images from referral centers in Essen, Germany, and Paris, France. Images were from 39 patients with retinoblastoma (16 male and 18 female patients [the sex in five patients was unknown]; age range, 5–90 months; inclusion criterion: pretreatment MR imaging). This atlas was used to compare MR imaging features with genome-wide messenger RNA (mRNA) expression data from 60 consecutive patients obtained from 1995 to 2012 (35 male patients [58%]; age range, 2–69 months; inclusion criteria: pretreatment MR imaging, genome-wide mRNA expression data available). Imaging pathway associations were analyzed by means of gene enrichment. In addition, imaging features were compared with a predefined gene expression signature of photoreceptorness. Statistical analysis was performed with generalized linear modeling of radiology traits on normalized log2-transformed expression values. P values were corrected for multiple hypothesis testing. Results: Radiogenomic analysis revealed 1336 differentially expressed genes for qualitative imaging features (threshold P = .05 after multiple hypothesis correction). Loss of photoreceptorness gene expression correlated with advanced stage imaging features, including multiple lesions (P = .03) and greater eye size (P , .001). The number of lesions on MR images was associated with expression of MYCN (P = .04). A newly defined radiophenotype of diffuse-growing, plaque-shaped, multifocal tumors displayed overexpression of SERTAD3 (P = .003, P = .049, and P = .06, respectively), a protein that stimulates cell growth by activating the E2F network. Conclusion: Radiogenomic biomarkers can potentially help predict molecular features, such as photoreceptorness loss, that indicate tumor progression. Results imply a possible role for radiogenomics in future staging and treatment decision making in retinoblastoma.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050352203&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29714679
U2 - https://doi.org/10.1148/radiol.2018172000
DO - https://doi.org/10.1148/radiol.2018172000
M3 - Article
C2 - 29714679
SN - 0033-8419
VL - 288
SP - 506
EP - 515
JO - Radiology
JF - Radiology
IS - 2
ER -